Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 11/20 | 0.49 |
| ▸ | F2 | P00734 | 9/20 | 0.49 |
| ▸ | TMPRSS11D | O60235 | 4/20 | 0.45 |
| ▸ | PLG | P00747 | 2/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.44 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.44 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | F7 | P08709 | 1/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14628420 | 1.00 | F10 (0.49) | F10F2TMPRSS11DPLGPRSS1 | |
| Hydrochloric Acid SCHEMBL6544352 | 0.99 | F10 (0.49) | F10F2TMPRSS11DPLGPRSS1 | |
| SCHEMBL13283064 | 0.91 | CA12 (0.47) | F10F2TMPRSS11DPLGPRSS1 | |
| SCHEMBL5497165 | 0.90 | F10 (0.42) | F10F2TMPRSS11DPLGPRSS1 | |
| SCHEMBL8346530 | 0.88 | F2 (0.57) | F10F2TMPRSS11DPLGPRSS1 | |
| SCHEMBL5499067 | 0.87 | F10 (0.42) | F10F2TMPRSS11DPLGPRSS1 | |
| Hydrochloric Acid SCHEMBL6544447 | 0.86 | F10 (0.42) | F10F2TMPRSS11DPLGPRSS1 | |
| SCHEMBL13456454 | 0.86 | F10 (0.54) | F10F2TMPRSS11DPLGPRSS1 | |
| SCHEMBL5495060 | 0.85 | F2 (0.48) | F10F2TMPRSS11DPLGF7 | |
| SCHEMBL14628111 | 0.85 | F2 (0.48) | F10F2TMPRSS11DPLGF7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080226624-A1 | Combined treatment of cancer by urokinase inhibition and a cytostatic anti-cancer agent for enhancing the anti-metastatic effect | WILEX AG (DE) | 2008-09-18 | — | — | US | claimed |
| EP-1453852-B1 | SELECTIVE UROKINASE INHIBITORS | WILEX AG (DE) | 2007-01-17 | — | — | EP | claimed |
| US-20040266766-A1 | Selective urokinase inhibitors | WILEX AG (DE) | 2004-12-30 | — | — | US | claimed |
| US-8093258-B2 | Use of urokinase inhibitors for the treatment and/or prevention of neuropathological diseases | WILEX AG (DE) | 2012-01-10 | — | — | US | disclosed |
| EP-1893185-B1 | USE OF UROKINASE INHIBITORS FOR THE TREATMENT AND/OR PREVENTION OF AMYOTROPhIC LATERAL SCLEROSIS (ALS) | WILEX AG (DE) | 2009-09-16 | — | — | EP | disclosed |
| EP-2087885-A1 | Use of urokinase inhibitors for the treatment and /or prevention of neuropathological diseases | Wilex AG (DE) | 2009-08-12 | — | — | EP | disclosed |
| US-20090069251-A1 | Use Of Urokinase Inhibitors for the Treatment and/or Prevention of Neuropathological Diseases | WILEX AG (DE) | 2009-03-12 | — | — | US | disclosed |
| US-20080226624-A1 | Combined treatment of cancer by urokinase inhibition and a cytostatic anti-cancer agent for enhancing the anti-metastatic effect | WILEX AG (DE) | 2008-09-18 | — | — | US | disclosed |
| EP-1893185-A2 | USE OF UROKINASE INHIBITORS FOR THE TREATMENT AND/OR PREVENTION OF NEUROPATHOLOGICAL DISEASES | Wilex AG (DE) | 2008-03-05 | — | — | EP | disclosed |
| EP-1453852-B1 | SELECTIVE UROKINASE INHIBITORS | WILEX AG (DE) | 2007-01-17 | — | — | EP | disclosed |
| EP-1453852-B1 | SELECTIVE UROKINASE INHIBITORS | WILEX AG (DE) | 2007-01-17 | — | — | EP | disclosed |
| WO-2006136419-A2 | USE OF UROKINASE INHIBITORS FOR THE TREATMENT AND/OR PREVENTION OF NEUROPATHOLOGICAL DISEASES | WILEX AG (DE) | 2006-12-28 | — | — | WO | disclosed |
| US-20040266766-A1 | Selective urokinase inhibitors | WILEX AG (DE) | 2004-12-30 | — | — | US | disclosed |
| EP-1453852-A2 | SELECTIVE UROKINASE INHIBITORS | Wilex AG (DE) | 2004-09-08 | — | — | EP | disclosed |
| WO-2003053999-A2 | SELECTIVE ARYLGUANIDINE PEPTIDES AS UROKINASE INHIBITORS | WILEX AG (DE) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266766-A1 | Selective urokinase inhibitors | PLAU, PLAUR, SERPINE1 | F10 128/4885F2 151/4885TMPRSS11D 44/4885 |
| US-20080226624-A1 | Combined treatment of cancer by urokinase inhibition and a cytostatic anti-cancer agent for enhancing the anti-metastatic effect | PLAU, PLAUR, SERPINE1 | F10 558/4885F2 822/4885TMPRSS11D 321/4885 |
| US-20090069251-A1 | Use Of Urokinase Inhibitors for the Treatment and/or Prevention of Neuropathological Diseases | PLAU, SERPINE1, PLAUR | F10 436/4885F2 710/4885TMPRSS11D 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.